Novel therapies and vaccines against the human respiratory syncytial virus

dc.date.accessioned2020-04-20T19:47:08Z
dc.date.accessioned2022-10-18T23:08:01Z
dc.date.available2020-04-20T19:47:08Z
dc.date.available2022-10-18T23:08:01Z
dc.date.created2020-04-20T19:47:08Z
dc.date.issued2015
dc.identifierhttp://hdl.handle.net/10533/241564
dc.identifier1100926
dc.identifierWOS:000365724700001
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/4472898
dc.description.abstractIntroduction: Human respiratory syncytial virus (hRSV) is the leading cause of acute lower respiratory tract infections worldwide in infants, as well as an important pathogen affecting the elderly and immunocompromised individuals. Despite more than a hal
dc.languageeng
dc.relationhttps://doi.org/10.1517/13543784.2015.1099626
dc.relation10.1517/13543784.2015.1099626
dc.titleNovel therapies and vaccines against the human respiratory syncytial virus
dc.typeArticulo


Este ítem pertenece a la siguiente institución